---
document_datetime: 2024-12-18 17:02:10
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vanflyta-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: vanflyta-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 1.3234841
conversion_datetime: 2026-02-09 22:12:16.951067
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## VANFLYTA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0005              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 16/12/2024                          |                                             | SmPC and PL                      |           |
| IB/0003              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                            | 01/08/2024                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/176/2 02312   | Periodic Safety Update EU Single assessment - quizartinib                                                                                                                                                                                                                                                                                                                                                                                                                | 11/07/2024   | n/a   |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002             | To update section 4.5 and 5.2 of the SmPC in order to add information on interaction with Breast cancer resistant protein (BCRP) substrates based on results from study GE-2161 - Inhibitory Effects of Quizartinib on the Transport Activity of BCRP (REC). In addition, the MAH is taking this opportunity to introduce editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/05/2024   |       | SmPC | SmPC new text: In vitro data indicate that quizartinib is an inhibitor of Breast cancer resistance protein (BCRP). The clinical relevance is currently not known. Caution should be used when quizartinib is co-administered with medicinal products that are substrates of BCRP. Quizartinib inhibits BCRP with an estimated in vitro IC50 of 0.813 Î¼M. As no clinical data is available, it cannot be excluded that quizartinib could inhibit this transporter at the recommended doses. |